Funding

Lys Therapeutics

France · Biotech · Healthtech

Develops monoclonal antibody LYS241 targeting neurovascular pathways for Parkinson's disease and stroke

Visit lys-tx.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Seed>€25MBpifrance — Role not disclosedFrance 2030 — Role not disclosedThe Michael J. Fox Foundation — Role not disclosed

Investors

BpifranceSeedFrance 2030SeedThe Michael J. Fox FoundationSeed

Coverage

Jun 22, 2026Lys Therapeutics · Seed

Similar companies

Guoke Brain-ComputerBeijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.Undisclosed · Seed
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
Sourceslys-tx.com ↗